Featured Story | | | Thursday, August 17, 2017 The director of UCSF's Cardiovascular Research Institute, Shaun Coughlin, M.D., Ph.D., has joined the ranks of senior academics heading to drugmaker Novartis. |
|
|
| This week's sponsor is FierceBiotech Drug Development Forum. | | | Save 15% on the FierceBiotech 2nd Drug Development Forum
90+ executive-level speakers share advanced partnership and pipeline strategies September 25-27 in Boston, MA. Learn to adapt to increased deal complexity, real world evidence, and digital technologies. Sign up today & save 15% w/ code C942FIERCE. |
Top Stories Thursday, August 17, 2017 Atreca has raised $35 million. The series B tees up Atreca to pick its first clinical candidate derived from a platform that has attracted the interest of a who’s who of Big Pharma players. Thursday, August 17, 2017 Fred Hutchinson Cancer Research Center has joined with two other groups and Context Therapeutics to research Sigma1. The collaborators hope to learn about the role that Sigma1 plays in disease and assess the activity of Context’s inhibitors of the protein. Thursday, August 17, 2017 Alzeca Biosciences raised $11 million in series A financing that will bolster the development of its MRI-based nanoparticle contrast agent, designed for the early detection of Alzheimer’s disease and other neurodegenerative disorders. Wednesday, August 16, 2017 Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) both cause a progressive loss of brain cells that scientists have so far failed to prevent. A Genentech-led team of academic and industry researchers has discovered a protein that, when blocked, reverses a signaling pathway that causes neurodegeneration in these conditions. Thursday, August 17, 2017 U.S. oncology specialist Cancer Genetics will pay $12 million to buy out Australian contract research organization vivoPharm as it looks to bolster its offerings. Wednesday, August 16, 2017 One day after committing to remain on President Donald Trump's manufacturing council, Johnson & Johnson CEO Alex Gorsky on Wednesday decided to bow out in the wake of new remarks from the president. The decision came about the same time Trump ended the panel, which the president announced via Twitter. Resources Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. 2nd Strategic Partnerships for Drug Repurposing Oct 26-27 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA 15th Annual Discovery on Target September 25-29, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA | 